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Many people living in Africa and elsewhere in the tropics suffer from combined malaria, soil-transmitted 
infections and tissue-dwelling nematodes. Most of these deaths are prevalent in sub-Saharan Africa 
(SSA) where the infections overlap, which often results in co-infection. Malaria and trichinellosis are 
one of the most important zoonotic diseases especially in sub-Saharan Africa caused by Plasmodium 
spp. and Trichinella spp., respectively. New drugs targeting malaria and trichinellosis have been 
examined with little success. The aim of our study was to determine and compare the efficacy of 
maslinic acid and chloroquine on the co-infection of muscle-dwelling larvae of Trichinella zimbabwensis 
and Plasmodium berghei in rats. Fifty-four Sprague-Dawley rats with an average weight of 150g and 
200g for males and females respectively were infected with T. zimbabwensis and P. berghei. Infected 
rats were randomly assigned to nine groups which were subjected to treatments of maslinic acid and 
chloroquine and a combination of maslinic acid and chloroquine. Co-infected groups were infected with 
T. zimbabwensis on day 0, and then infected with P. berghei on day 30 post-infection (pi). Treatment 
was administered for 3 consecutive days on day 9 pi with P. berghei. Groups infected with P. berghei 
only were infected on day 0 and were treated on day 9 pi for 3 consecutive days. Groups infected with T. 
zimbabwensis only were infected on day 0 and treated on day 25 pi. Untreated control groups were a 
placebo (distilled water) on day 25 pi infected with T. zimbabwensis and from day 9 pi infected with P. 
berghei. In Trichinella-infected groups, the efficacy of each treatment measured by the rate of the 
reduction in muscle larvae was significant (P < 0.05) for both drugs compared to the untreated control 
group. In malaria-infected groups, the efficacy of each treatment, measured by the rate of reduction in 
parasitaemia, was significant (P < 0.05) for both drugs compared to the untreated control group. There 
was no apparent synergistic effect due to the combination of the two drugs in reducing the muscle larval 
burden and in reducing malaria parasitaemia. In all the treatment regimens, the reductions were 
significant when compared to the untreated control groups and not significant to each other (P > 0.05). 
From these results we can conclude that the efficacy of maslinic acid on the co-infection of T. 
zimbabwensis and P. berghei was comparable to that of chloroquine, making maslinic acid a promising 
drug to be used as an anthelmintic and anti-malaria against muscle larval stages of Trichinella spp. and 
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Malaria – infectious disease characterized by cycles of chills, fever and sweating, caused by the parasitic 
infection of red blood cells by the protozoan of the genus Plasmodium. 
Trichinellosis – disease caused by the genus Trichinella, typically from infected meat, characterized by 
digestive disturbance, fever and muscular rigidity. 
Benzimidazole – a crystalline base C7H6N2 used especially to inhibit the growth of various viruses, 
parasitic worms or fungi. 
Definitive host – host in which the parasites have sexual reproduction. 
Intermediate host – host in which parasites grow and either do not reproduce or do so asexually. 
Mass drug administration – administration of a full therapeutic course of an antimalarial drug to a 
whole population without screening for the presence of parasitaemia. 
Intermittent preventative treatment – administration of full course antimalarial treatment at a specific 
time without parasite evaluation. 
Soil-transmitted helminths - refers to the intestinal worms infecting humans that are transmitted through 










Malaria is a common and life-threatening disease in many tropical and subtropical areas (WHO, 2012). It 
is a vector-borne disease, caused by protozoa of the genus Plasmodium (WHO, 2013). The species that 
cause human malaria are P. falciparum, P. vivax, P. ovale, P. malariae (WHO, 2013) and one simian 
parasite, P. knowlesi transmitted by Anopheles dirus in communities living in or near forested areas of 
southeast Asia (WHO, 2012). In sub-Saharan Africa, P. falciparum parasite is transmitted to humans by 
female Anopheles mosquito during a blood meal (Gonçalves et al., 2014). Children under 5 years of age 
(WHO, 2014), women in their first pregnancy (WHO, 2014) and travelers from areas that are malaria free 
are mainly affected by malaria caused by P. falciparum (WHO, 2014).   The most deadly species are P. 
falciparum, which is widely spread geographically, and P. vivax, which is less infective, but relapsing 
(WHO, 2012).  In 2010 it was estimated that 98% cases of malaria in Africa were caused by P. 
falciparum, while in South-East Asia 50% of the cases were caused by P. vivax (WHO, 2012). Between 
2000 and 2013, an expansion of malaria interventions helped to reduce malaria incidence by 30% 
globally, and by 34% in Africa (WHO, 2014). P. berghei is the causative agent of rodent malaria and is 
widely used as a model system to study various stages of Plasmodium parasites that affect humans (van 
de Sand et al., 2005) 
The biological diversity during the life cycle of the Plasmodium parasite is one of its vital characteristics 
(WHO, 2012). A human is infected with a bite from a mosquito carrying malaria. Parasites which are in 
the form of sporozoites occupy the liver cells where they are able to multiply over a few weeks. Once in 
the liver, the sporozoites become merozoites. The merozoites will leave the liver and enter into the 
bloodstream. When they are in the bloodstream they start infecting erythrocytes and start replicating 
asexually. The replication results in clinical signs in infected people such as changes in blood flow and 
vascular endothelium, systemic complications due to anemia, fever and other flu-like symptoms due to 
the release of cytokines (WHO, 2012). Some merozoites remain in the erythrocytes and develop into 
sexual forms, called gametocytes (WHO, 2012). The gametocytes will remain in the bloodstream until a 
mosquito feeds on the infected human and ingests the infected blood. Once the gametocytes are on the 
mosquito, they will replicate to form sporozoites (WHO, 2012).The three forms of malaria parasites are 
biologically diverse, resulting in different responses to diagnostic tools, vaccines and pharmaceuticals 
(WHO, 2012).  
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One of the leading causes in morbidity and mortality in people leaving in sub-Saharan Africa is malaria 
however; the gravity of the disease varies from person to person (Legesse et al., 2004). Populations living 
in the same areas affected by malaria may show differences in susceptibility to Plasmodium infection and 
development of acute malaria (Leggese et al., 2004).  Some of the factors such as age, pregnancy, host 
genetic factors, immunity, inoculation dose and virulence of the parasite strains have been contemplated 
to influence the acute phase of the disease (WHO, 2012). The WHO recommended a coherent approach to 
control and prevent the disease by using insecticide treated bed nets (ITNs) and indoor residual spraying 
(IRS), chemoprevention and case management of infected people (White et al., 2014). All these methods 
have managed to decrease the occurrence of malaria, morbidity and mortality globally (WHO, 2014). 
However, because of the rising emergence of drug resistant Plasmodium parasites and insecticide resistant 
mosquitoes the goal towards eliminating and eradicating malaria is being compromised (White et al., 
2014). 
 
Trichinellosis is a widespread zoonosis, acquired through ingestion of raw or undercooked meat infected 
with the first stage larvae of the parasite (Soliman et al., 2011). The infected meat contains infective 
larvae of Trichinella spp. (Soliman et al., 2011). Human infections are mostly accidental and caused by 
Trichinella spiralis (Momoh et al., 2012). Between 1986 and 2009, an average of 2739 cases and two 
deaths were reported per year (Murrell and Pozio, 2011). The first known estimate of the global burden of 
trichinellosis expressed in DALYs was estimated to be 76 per billion persons per year (Devleesschauer et 
al., 2015). The common signs and symptoms of trichinellosis in man include fever, diarrhea, periorbital 
oedema and myalgia (Dupouy-Camet et al., 2007). According to Soliman et al. (2011) trichinellosis is 
regarded as a significant disease globally.  
 
The normal life cycle of Trichinella involves humans, pigs, rodents and reptiles. Pigs are infected by 
ingesting raw or undercooked pork or rats, and humans become infected by ingesting raw or undercooked 
pork meat (Momoh et al., 2012). All stages of development occur in a single host. However there are two 
hosts required in completing the life cycle, primary host is the pig and the natural hosts are rodents, 
carnivores and various other species of omnivorous animals (Momoh et al., 2012). Man is the accidental 
host and when infected the adult worms which develop within 48hours will reside in the small intestine 
(Soliman et al., 2011). After fertilization the gravid female discharges the larvae which enters most 
organs but only persists in the skeletal muscles (Soliman et al., 2011). The larvae will be encapsulated 
(depending on the species) in the muscles (Yadav and Temjenmongla, 2011).  
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The disease is significantly high in prevalence globally and it is reported that prevalence is increasing in 
developing and developed countries (Bruschi, 2012). Globally, eight species and four genotypes of the 
genus Trichinella have been recognized (Gottstein et al., 2009). Until recently, reports only show that 
Trichinella spiralis was known to be found in sub-Saharan Africa (Mukaratirwa et al., 2013). Recent data 
shows that Trichinella britovi, Trichinella nelsoni, Trichinella zimbabwensis and Trichinella T8 also 
occur in sub-Saharan Africa (Mukaratirwa et al., 2013). Trichinella zimbabwensis is classified as a non-
encapsulating Trichinella species due to the absence of a collagen capsule surrounding the larvae in host 
musculature (Mukaratirwa et al., 2013). Experimental studies with T. zimbabwensis in mammals and 
reptiles showed larvae of this parasite species to be larger in poikilothermic hosts than in mammalian 
hosts and is probably due to the host metabolic rate (Le Grange and Mukaratirwa, 2012). This species is 
similar to T. papuae and has been found only in wild and farmed reptiles of Africa (Zimbabwe, 
Mozambique, South Africa and Ethiopia) (Pozio et al., 2007). Human infections by T. papuae are not 
known so far (Gottstein et al., 2009). Trichinella zimbabwensis natural infection has only been reported in 
Crocodylus niloticus, Varanus niloticus and Panthera leo (Mukaratirwa et al., 2013).  According to 
Mukaratirwa et al., (2012) Trichinella zimbabwensis infects caimans, varans, pythons, turtles, rodents and 
domestic pigs experimentally. 
 
High prevalence of Trichinella zimbabwensis infections have been described among a diversity of 
mammals and reptiles in Southern Africa (Mukaratirwa et al., 2008; 2013). This poses a public health risk 
of future human epidemic outbreaks of trichinellosis in poor communities who depend on bush meat for 
protein (Mukaratirwa et al., 2013).  Trichinella zimbabwensis is a tissue-dwelling nematode that has a 
complex life cycle in one host. The migrating first stage larvae get localized in the host striated muscles 
for long periods of time (Mukaratirwa et al., 2008) contrary to the case of soil-transmitted helminths 
whose larvae settle in the lumen of the gastrointestinal tract.  
 
Human trichinellosis can be treated with various benzimidazole derivatives, such as mebendazole, 
albendazole and flubendazole (Mukaratirwa et al., 2013). However, none of these drugs are believed to be 
fully effective against the encysted or newborn larvae of T. spiralis, because of their low bioavailability 
(Soliman et al., 2011). Thus, new effective drugs are needed to help prevent and control this important 
zoonotic disease. 
Epidemiological studies and laboratory experiments have been conducted over the last three decades to 
elucidate the mechanisms and outcomes of parasite-host-parasite and host-parasite interactions in malaria 
and helminth co-infections but the results obtained do not show a general consensus (Brooker et al., 2007; 
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Degarege et al., 2012). Furthermore, chronic intestinal helminthic infections in humans have also become 
the subject of hypothesizing and exploration in malarial severity (Legesse et al., 2004). In a subset of 
experiments with P. berghei on cerebral malaria models, helminth co-infection significantly reduced 
death (Knowles, 2011). It is has also been declared that intestinal helminthic infections are related with 
protection from cerebral malaria, malaria-related acute renal failure and jaundice (Ojurongbe, 2011). The 
conflicting findings may be attributed to multiple confounding factors like; discrepancy in study designs, 
parasite polymorphisms, human population diversity and genetic polymorphisms, exposure history, 
antibody cross reactivity and nutritional status (Brooker et al., 2012). In addition, the majority of the 
studies have focused on soil-transmitted helminths, schistosomes and filarial worms neglecting the effect 
of tissue-dwelling helminths and effect of deworming or mass drug administration (MDA) programs that 
are in place in malaria endemic subtropical and tropical areas. There is a need to develop effective 
vaccines, sensitive diagnostic tools and identification of drug candidate molecules through understanding 
host-parasite interactions elicited during co-infections with tissue-dwelling nematodes like T. 
zimbabwensis. 
The aim of this study is to determine the anthelmintic and anti-malarial effect of maslinic acid and 
chloroquine on the co-infection T. zimbabwensis and P. berghei on Sprague-Dawley rats. The general 
objective is to determine efficacy of maslinic acid on Sprague-Dawley rats co-infected with P. berghei 
and T. zimbabwensis and if there any synergistic effect on the combination maslinic acid and chloroquine 
on co-infected rats. 
Specific objectives of the study: 
1. Determine the efficacy of maslinic acid against the co-infection of Trichinella zimbabwensis 
muscle larvae and Plasmodium berghei parasitaemia in laboratory rats. 
2. Determine the efficacy of chloroquine against the co-infection of Trichinella zimbabwensis 
muscle larvae and Plasmodium berghei parasitaemia in laboratory rats. 
3. Determine the efficacy of the combination of maslinic acid and chloroquine against the co-
infection of Trichinella zimbabwensis muscle larvae and Plasmodium berghei parasitaemia in 









Malaria poses a large health burden and Africa has more than 70% of the global clinical cases caused by 
Plasmodium (WHO, 2014). It is still one of the most significant infection diseases causing over 655 000 
deaths per year, of which the majority of those deaths are children under 5 years of age (Sauerwein et al., 
2012). There has been a decrease of more than 50% of either confirmed malaria cases or morbidity and 
mortality cases in eleven countries of the WHO African region through intense malaria control regions 
(WHO, 2011a). However, increase of malaria cases in 2009 in Rwanda, Sao Tome and Principe and 
Zambia has shown the weakness of the current successes (Sauerwein et al., 2012). This emphasizes the 
importance for additional and inventive strategies to control malaria (Sauerwein et al., 2012). 
 
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale and Plasmodium 
knowlesi parasites infect humans under normal conditions (WHO, 2012) with P. falciparum and P. vivax 
being the major species that cause morbidity and mortality in children under five years of age, pregnant 
women and travelers from non-malarious areas (Warimwe et al., 2013). P. berghei is a strain that affects 
rodents and mostly used as model for malaria experiments. In sub-Saharan Africa, morbidity and 
mortality due to malaria is decreasing despite a lack of a malaria vaccine, emergence of parasite 
resistance to available anti-malarial drugs, the female anopheles mosquito being resistant to IRS and a 
poor socio-economic situation that hinders malaria control and management (WHO, 2012). New drug 
discovery and vaccine development are delayed by limited knowledge of the underlying cellular and 
molecular mechanisms of host-parasite interactions during co-infection and polyparasitism (Good and 
Doolan, 2010; Nossal, 2011). This is also worsened by the emergence of zoonotic P. knowlesi malaria 
infections (Cox-Singh, 2012; Fan et al., 2013) as well as other zoonotic infectious diseases. 
 
Trichinellosis is an emerging and re-emerging zoonotic disease the geographical distribution of which 
overlaps with malaria in endemic areas of Tanzania, Uganda, Kenya, Ethiopia, Zimbabwe, South Africa 
and Mozambique (Gottstein et al., 2009; Le Grange et al., 2012, 2010, 2009; Mukaratirwa et al., 2013; 
Murrell and Pozio, 2011). More recent studies have reported on more species other than the most 
commonly known, Trichinella spiralis (Pozio, 2013). The genus Trichinella now encompasses eight 
species (Pozio, 2013). The twelve identified taxa are genetically and biologically delineated by two clades 
distinguished by encapsulated and non-encapsulated larvae in the host muscle tissue (Zarlenga et al., 
2006). The encapsulated species are found in mammals only and the non-encapsulated species are found 
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in mammals, birds (one species) and some reptiles (Pozio and Murell, 2011). T. spiralis is the most 
common species to domestic and wild pigs but it can also involve synathropic rats in its life cycle 
(Gottstein et al., 2009). T. spiralis has a wide vast and global distribution and also is the important 
causative agent of human trichinellosis (Pozio and Murell, 2011).  
 
Until recently, all Trichinella infections found in animals and humans in SSA were regarded to be caused 
by T. spiralis (Mukaratirwa et al., 2012). The existing data shows that T. britovi, T. nelsoni, T. 
zimbabwensis and T8 are found in SSA (Mukaratirwa et al., 2012). Regardless of being reported as found 
globally, T. spiralis has not yet been reported in SSA (Mukaratirwa et al., 2012). Trichinella nelsoni is 
only found on the Eastern and Southern part of the sub-Saharan region (Mukaratirwa et al., 2012); 
reported in Kenya, South Africa and Tanzania (Marucci et al., 2008). Trichinella T8 has been described 
to occur in Southern African countries (Marucci et al., 2008). The presence of this species in South Africa 
and Namibia has been accredited to possible introduction from Europe but research in Guinea and the 
successive re-evaluation of the distribution of encapsulated Trichinella spp. and specifically T. britovi 
suggests a more natural explanation (Marucci et al., 2009).  Reports earlier describing encapsulated 
Trichinella spp. larvae in South Africa (Young and Kruger, 1967; Young and Whyte, 1975) could 
possibly have been T. nelsoni or Trichinella T8 now known to be found in that country (Marucci et al., 
2009). Earlier investigations of Trichinella spp. in Kenya and Tanzania (Forrester et al., 1961; Forrester, 
1964; Nelson, 1970) could possibly have been T. nelsoni and T. zimbabwensis which circulate in 
Southern and Eastern areas of SSA and have so far been found in Zimbabwe, South Africa, Mozambique 
and Ethiopia (La Grange et al., 2009, 2010, 2012).  
 
Many drugs have been used to treat trichinellosis, however there is lack of an effective drug against 
tissue-dwelling nematodes due to increasing drug resistance. The development of vaccines against 
parasitic infections has been complicated due to the fact that co-infecting parasites have life cycles that 
are either direct or complex. Direct life cycles involve cycling of mature parasites from one definitive 
host to another while complex life cycles involve cycling of distinct developing life stages through a 









2.2 Co-infection of malaria and tissue-dwelling nematodes in sub-Saharan Africa 
Epidemiological studies have shown that the largest burden of malaria infections is felt by communities 
living in poor regions of developing countries (Boraschi et al., 2008; Brooker et al., 2007; Shankarkumar 
et al., 2011). In these areas, the wide spread of soil-transmitted helminthic infections have also been 
documented (Mwangi et al., 2006). This results in co-infections, multi-parasitism or polyparasitism 
(Supali et al., 2010). In the past three decades, many studies have been undertaken to determine the nature 
of interaction that occurs between soil-transmitted helminths (STHs) and malaria during co-infection 
scenarios. The studies have mainly focused on immunological aspects and disease outcomes neglecting 
non-immunological mechanisms that may explain the heterogeneity observed in these studies (Fenton et 
al., 2014; Knowles, 2011). Varying conclusions have been made from both epidemiological studies and 
laboratory experiments. Some studies have established that helminths may confer protection against 
cerebral malaria, others indicate that helminths exacerbate malaria, others report a reduction or increase in 
prevalence and transmission of malaria, while a few others report no association between the parasites 
(Bejon et al., 2008; Nacher, 2011; Roussillon et al., 2010).  
 
The lack of general consensus in the studies is evidence that malaria immunity is not well understood. 
However, it is argued that STHs influence clinical malaria disease presentation or confer malaria 
tolerance through the establishment of chronic infections, induction of adaptive immunity and 
immunosuppression of immune responses to unrelated antigens and parasites (Taylor et al., 2012). These 
result in an induction of host regulatory immunity, and signaling and effector mechanisms (Ashour, 2013; 
Brindley et al., 2009; Maizels et al., 2009) that are beneficial to co-infecting parasites. This is mainly due 
to host’s failure to regulate the immune responses induced by the parasites. During co-infections, one 
parasite does not have direct influence on disease outcome and establishment of another parasite, 
however, the concept of parasite-host-parasite interactions plays a key role. One parasite influences the 
host to induce immune responses that will favor its establishment which in the long run, become 
beneficial to the co-infecting parasite. This immunological phenomenon is parasite-driven to make the 
host susceptible to infection and not favor the establishment of the co-infecting parasite. The amelioration 
or exacerbation of the disease outcome of the co-infecting parasites is a spill-over effect. 
In the majority of co-infection studies, tissue-dwelling parasites, prevalent in sub-Saharan Africa, have 
not been adequately considered. The hypothetical arguments presented are sketchy, making it difficult to 
clearly predict disease outcomes during malaria interaction with tissue-dwelling parasites. Therefore there 




There are few studies that are directed towards elucidating the host-parasite interactions and disease 
outcomes that are caused by tissue-dwelling parasites during co-infection with malaria. This has created a 
glaring paucity of data on understanding the mechanisms and outcomes of tissue-dwelling parasites and 
mono-and co-infection with malaria. This has also hampered diagnosis, vaccine development, drug 
discovery, and management and control of these emerging and re-emerging parasites. 
 
2.3 Epidemiology of co-infection of malaria and trichinellosis 
Sequences of single parasite species infection of helminth or P. falciparum have been well reported 
during classical epidemiology (Brooker et al., 2007). Both types of parasites show clearly that age is 
dependent on infection sequences (Brooker et al., 2007). Epidemiological studies based on age have 
shown that that the prevalence of asymptomatic Plasmodium infections increases in early childhood, and 
starts to decrease with the moderate acquired immunity (Brooker et al., 2007). The rate at which this 
immunity is acquired is relative to exposure, but in areas of low transmission infections in adulthood are 
generally low (Brooker et al., 2007).  
 
Helminths are widely distributed, with most people having little or no worms and the majority of the 
worm population found in a minority of individuals (Knowles, 2011); it is within the minority group that 
most relative incidence occurs. The same patterns of wide distribution are also seen for P. falciparum 
infections (Brooker et al., 2007). Earlier modeling of the prevalence of the parasite and its reproduction 
rate of infection implies that 20% of children in a community get 80% of new infections in a community 
(Smith et al., 2005). Both malaria and helminth infections have a likelihood to occur within certain 
families and households (Knowles, 2011).  
  
Currently, human trichinellosis has been reported in only four countries (8.7%, 4/46) of SSA; Ethiopia, 
Kenya, Senegal and Tanzania (Mukaratirwa et al., 2012). Four species reported in SSA are T. britovi, T. 
nelsoni, T. T8 and T. zimbabwensis (Mukaratirwa et al., 2012). Ethnic minorities and tourists are the ones 
mainly reported to have human trichinellosis, with less than 100 reported human infections in the region 
(Pozio, 2007). The low prevalence of human trichinellosis in the region has been ascribed to the 
consumption of well-cooked meats and religious beliefs prohibiting the consumption of pork (Pozio et al., 
2013. The causative agents of human trichinellosis in sub-Saharan Africa have not yet been recognized to 
the species or genotype level (Mukaratirwa et al., 2013). The zoonotic potential of both Trichinella T8 
and T. zimbabwensis is currently unknown (Mukaratirwa et al., 2013). However, T. zimbabwensis was 
displayed to infect non-human primates and the clinical signs described were similar to those described in 




At present, there are no studies on the epidemiological details of the co-infection of malaria and 
trichinellosis. However, what is currently known about the epidemiology of co-infection, it is proposed 
that school-going children, rather than pre-school children or adults, are most at-risk of Plasmodium-
helminth co-infection, and to bear greatest risk of the consequences of co-infection (Knowles, 2011).  
 
2.4 Conventional drugs for malaria 
The resistance of drugs to malaria has become an important issue in malaria control. Drug resistance in 
vivo has been reported against almost all antimalarial drugs currently used for malaria control (Valecha et 
al., 2016).  P. falciparum and P. vivax have been reported to be resistant against antimalarial drugs 
(Valecha et al., 2016).  P. falciparum is not only resistant to chloroquine alone, but also to the other 





Figure 1. Chemical structure of chloroquine. 
 
Chloroquine-resistant P vivax was first reported in 1989, almost 30 years after chloroquine-resistant P 
falciparum was first noted (Baird et al., 1991). The absence of reliable, robust, sensitive methods for 
detection, mapping, and monitoring of antimalarial drug efficacy in P vivax has almost certainly 
contributed to the delayed recognition of this emerging problem (Price et al., 2011). This delay has had 
important public health implications. The resistance of P. falciparum malaria to chloroquine has been 
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described to be widespread (The Lancet, 2014). The first cases of P. falciparum resistance to chloroquine 
were reported in Southeast Asia and South America (Colombia) in late 1950s (Spencer, 1985; Young and 
Moore, 1961; Wernsdorfer and Payne, 1991). Since then chloroquine resistance has spread and is now 
found in all parts of the world where malaria is endemic (The Lancet, 2014). The first case of chloroquine 
resistance in Africa was first reported in the eastern part in 1978 (Wernsdorfer and Payne, 1991; Peters, 
1987), which then spread to the central and southern parts before being described in West Africa in 1983 
(Peters, 1987; Pickard and Wernsdorfer, 2002). By 1989 chloroquine resistance was already widely 
distributed in sub-Saharan Africa (Peters, 1987). The seriousness of resistance was more in east Africa 
than in west and central Africa, but even in West Africa, the potency of resistance varied from a 
progressed stage with severe effects on morbidity and mortality in focal areas of Senegal to a moderate 




Figure 2. Chemical structure of quinine.  
 
The initial case to quinine resistance was reported about a century in South America (Farooq and 
Mahajan, 2004). It was reported from the Thai-Cambodian border in mid 1960s (Pickard and 
Wernsdorfer, 2002). Quinine is now used to treat severe cases of malaria and, as a second line treatment, 
in combination with antibiotics to treat resistant malaria. Its short half-life of 8– 10 h likely contributed to 
the scarcity of widespread quinine resistance (Petersen, 2011).  The molecular mechanism by which 
quinine acts against P. falciparum is only partially understood. Similar to chloroquine, quinine has been 
demonstrated to accumulate in the parasite’s digestive vacuole (DV) and can inhibit the detoxification of 
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heme, an essential process within the parasite (Petersen, 2011). Recent studies show that the genetic basis 
for resistance to quinine is complex, with multiple genes influencing susceptibility (Petersen, 2011). 
Quinine has since been used in combination with tetracycline or doxycycline to improve its effectiveness 




Figure 3. Chemical structure of mefloquine. 
 
Mefloquine resistance was initially described in late 1980s near the Thai-Cambodian border (Shanks, 
1994). Resistance to mefloquine is mediated by amplification of pfmdr1, leading to overexpression of this 
resident DV membrane transporter (Petersen et al, 2011). Although the exact mechanism of action 
remains unclear, in vitro experiments demonstrate that mefloquine can bind to heme and exert some 
antimalarial activity by inhibiting heme detoxification (Petersen et al, 2011). However, studies on 
transgenic parasites expressing different pfmdr1 copy numbers, observed a reduced parasite susceptibility 
to mefloquine with increased PfMDR1-mediated import into the DV (Petersen et al., 2011), suggesting a 
primary mode of action outside of the DV (Petersen et al, 2011). Additionally, it has been shown that 
mefloquine inhibits the import of other solutes into the DV and might therefore also target the PfMDR1 







Figure 4. Chemical structure of artemisinin. 
 
Artemisinin and its derivatives were most efficacious antimalarial drug (Farooq and Mahajan, 2004). 
These drugs exert influence on the protein synthesis of the parasite (Farooq and Mahajan, 2004). In recent 
years, parasite resistance to artemisinin has been detected in five countries of the Greater Mekong sub 
region: Cambodia, the Lao People’s Democratic Republic, Myanmar, Thailand and Viet Nam. In areas 
along the Cambodia–Thailand border, P. falciparum has become resistant to most available antimalarial 
medicines, and multi-drug resistance is a major concern (WHO, 2014). 
 
2.5 The emergence of chloroquine resistance 
Chloroquine has been the most researched drug but its method of action still remains to be explained 
(Farooq and Mahajan, 2004). The method of the antimalarial action of quinolone containing drugs such as 
chloroquine has been researched by many workers and many therapeutic targets have been proposed 
(Farooq and Mahajan, 2004). The acid food vacuole of the parasite has most of the drug targets (Petersen 
et al., 2011). The resistance of P. falciparum to chloroquine is suspected to be caused by the increased 
capacity for the parasite to remove chloroquine at a rate that does not allow chloroquine to reach levels 
required for inhibition of heamepolymerization (Petersen et al., 2011). This chloroquine efflux occurs at a 
rate that is 40 to 50 fold faster among resistant parasites than that in sensitive ones(Petersen et al., 2011). 
Further, proof which supports this mechanism is given by the fact that chloroquine resistance would be 
altered by drugs which interfere with this efflux system (Petersen et al., 2011) but the biochemical basis 
of this efflux is lacking of discussion. The efflux of chloroquine and in fact the entire chloroquine 
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resistant phenotype can be altered with Ca+ channel blocker, such as verapamil and diltiazem (Petersen et 
al., 2011).   
  
2.6 Conventional drugs for trichinellosis 
There is no effective vaccine for controlling trichinellosis diseases; therefore the treatment and 
prophylaxis is based on anthelmintic drugs (Taman and Azab, 2014). These drugs are aimed at 
eliminating helminthes from the host body through affecting different targets with various mechanisms 
(Taman and Azab, 2014). Drugs administered for trichinellosis include anthelmintics, 
glucocorticosteroids and preparations that compensate for protein and electrolyte deficits (Gottstein et al., 
2009). Anthelmintics are the primary drugs for treatment of trichinellosis (Gottstein et al., 2009). They 
include primarily albendazole (Zentel; Smith-KlineBeecham) and mebendazole (Vermox, Jansen 
pharmaceutical, and Beerse, Belgium) (Gottstein et al., 2009). Albendazole is one of the most commonly 
used drugs for trichinellosis (Taman and Azab, 2014). It acts on all developmental forms of the 
alimentary tract of the parasite (Taman and Azab, 2014). Mebendazole is also used to treat trichinellosis, 
though is poorly absorbed from the intestinal lumen, but it is well tolerated (Taman and Azab, 2014). 
Both albendazole and mebendazole are contraindicated during pregnancy and not recommended for 
children aged less than 2 years old (Taman and Azab, 2014).  Pyrantel (Combantrin) paralyzes parasite 
muscles by blocking their nerve endings. It is not absorbed from the intestinal lumen (Taman and Azab, 
2014). It interferes with neurotransmission by inhibiting acetylcholine esterase enzyme in helminthes and 
induces persistent activation of nAChR, resulting in worm irreversible spastic paralysis (Taman and 
Azab, 2014). More than 50% of the drug is excreted in stools in the form of metabolites and around 7% is 
excreted in urine, in original form or in the form of metabolites (Taman and Azab, 2014). A study done 
by Mukaratirwa et al. (2014), showed that fenbendazole and levamisole are effective against Trichinella 
zimbabwensis even though the parasite was not completely cleared from the host.   
 
The administration of anthelmintics at the intestinal stage invasion with the aim of removing intestinal 
forms of Trichinella sp. from the lumen of the gastrointestinal tract is of significance importance for an 
early and effective therapy, especially in the first 3 days following the infection. If administered early, 
such intervention prevents successive muscular invasion and development of disease. Efficacy of these 
anthelmintics at various stages of trichinellosis in humans continues to be the topic of many studies and 
discussions because of increasing resistance of the parasite to the drugs (Taman and Azab, 2014). There is 
no known effective treatment for trichinellosis especially drugs targeting all three stages and as a result 




2.7 Potential drug for malaria and trichinellosis 
2.7.1 Maslinic acid 
Maslinic acid (MA) is a natural olenane-type pentacycle triterpene found in the olive fruit and from 
acquired from olive pomace oil (Gradia- Granados et al., 1998). Reports have shown that this compound 
has activities such as anti-tumor, anti- oxidant, HIV protease inhibitor, antimicrobial, vasorelaxation and 
anti- diabetic action (Moneriz et al., 2011). It has been reported to show low toxicity in anti-tumor cells, 
an indication that it is safe to use for humans (Juan et al., 2008; De Pablos et al., 2010). Several reports 
have shown that MA has an anti-malarial activity (Carlos et al., 2011). Maslinic acid has also been shown 
to inhibit growth in Toxoplasma gondii cultures (Moneriz et al., 2011) and of recent anthelmintic 
activity against the muscle larval stage of Trichinella zimbabwensis in Sprague-Dawley rats 
(Mukaratirwa et al., 2014). 
 
Figure 5. Chemical structure of maslinic acid. 
 
Plants with medicinal properties, such as Cornus kousa, Junillia aspera, Malus pumila, and 
Ulmus pumila are known to have low concentrations of maslinic acid (Lozano-Mena et al., 
2014), the waxy skin of Olea europaea L. is reported to have a concentration as high as 80% 
(Lozano-Mena et al., 2014). In previous decades, there has been growing interest in developing 
new natural products which would be beneficial on health. As a result maslinic acid has been 
extracted in various plants used in traditional herbal medicine, also in vegetables and fruits 
(Lozano-Mena et al., 2014).Similarly, the biological activities of maslinic acid have been evaluated in 
various experimental models, from tumor cell lines to animal models of several diseases, supported by the 
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lack of adverse effects in vivo after the oral administration of the triterpene (Sanchez-Gonzalez et al., 
2013). In summary, maslinic acid is rising as a new natural and safe product with diverse biological goals, 
which might develop to considering it as a potential drug in the future. 
 
2.7.2. Biosynthesis and role as phytoalexin 
Triterpenoids, such as maslinic acid, are a group of secondary metabolites resulting from the cyclation of 
squalene, oxidosqualene or bis-oxidosqualene (Xu et al., 2004). These precursors (C30) are substrate of 
several types of triterpene synthases, which catalyze their cyclation through intermediate cations to a wide 
variety of triterpenes. Depending on the number of rings, the latter are classified as mono-, bi-, tri-, tetra- 
or pentacyclic triterpene alcohols (Xu et al., 2004). Lupeol, α- and β-amyrin are examples of pentacyclic 
triterpene alcohols, which not only constitute secondary metabolites themselves, but also might undergo 
oxidation reactions to yield other derivatives, such as betulinic, ursolic and maslinic acids (Xu et al., 
2004). 
 
Not long after Crataegus oxyacantha L. was identified, Tschesche et al. (1959) recognized maslinic acid 
as a derivative of the β-amyrin series, and then Stiti et al. (2007) suggested the biosynthetic pathway that 
leads to the formation of maslinic acid in the fruits of Olea europaea L., one of the main natural sources 
of this triterpene. Stiti et al. (2007) suggest that in the developing olive both the sterols (primary 
metabolites) and the non-steroidal triterpenoids (secondary metabolites) share oxidosqualene as a 
common precursor. The enzyme β-amyrin synthase catalyzes its cyclation into β-amyrin, and further 
oxidation steps give rise to the triterpenic dialcohol erythrodiol followed by the hydroxyl pentacyclic 
triterpenic acids oleanolic and maslinic (Stiti et al., 2007).  
 
 
2.7.3. Natural sources  
MA was initially identified in Crataegus oxyacantha L., but the rising attention in this triterpene because 
of its extensive range of health-boosting activities has led to its documentation in other natural sources, 
being existent in more than 30 plants globally (Lozano-Mena et al., 2014). On one hand, the triterpene 
has been found in plants used in traditional Asian medicine for the treatment of diverse affections. To 
reference only a few examples, the leaves of loquat (Eriobotrya japonica) (Lu et al., 2009), which have 
been used as antitussive and anti-inflammatory for chronic bronchitis, and also as diuretic, digestive and 
antipyretic (Banno et al., 2009); the flowers of Campsis grandiflora, employed for female disorders like 
uterine hemorrhage (Kim et al., 2005); the whole plant of Geum japonicum used as diuretic; and 
Agastache rugosa, for the treatment of anorexia, vomiting and other intestinal disorders (Shin and Khang, 
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2003). On the other hand, maslinic acid has newly been measured in edible vegetables, such as table 
olives, spinach and eggplant, aromatic herbs like mustard and basil (Lin et al., 2011; Yin et al., 2012), 
legumes such as chickpeas and lentils (Kologeropoulos et al., 2010), and to a lesser extent in some fruits 
like mandarin and pomegranate (Li et al., 2011). Therefore, plant-based diets might offer a constant 
supply of maslinic acid, which could be considered, among many other factors, partially responsible of 
the health-enhancing properties of these dietary habits. 
 
2.7.4. Antimalarial and anthelmintic properties of maslinic acid  
 Xu et al. (1996) first published the reports that showed the biological activities of maslinic acid, and 
defined the anti-HIV properties of several triterpenic acids isolated from the methanolic extract of Geum 
japonicum. Although the study did not offer mechanistic details of the inhibitory effect on HIV-1 
protease, it is clearly specified that maslinic acid was the most effective compound (Xu et al., 1996). 
Although neither the antiviral nor the antibacterial activities of maslinic acid have been further studied 
thoroughly, the protective effect of the triterpene against parasitic infections has given rise to much 
interest in recent years.  
 
De Pablos et al. (2010) showed that maslinic acid inhibited the entrance of Toxoplasma gondii into Vero 
cells in a dose-dependent manner, with IC50 of 8 μM at 48 hours of treatment. The fundamental 
mechanism appeared to be the inhibitory activity of the triterpene against proteases secreted by the 
parasite, which are important for the proteolytic processing of other proteins that contribute in the 
invasion of host cells. The gliding motility was also blocked by up to 100% by maslinic acid (50 μM) (De 
Pablo et al., 2010). Furthermore, the triterpene induced morphological alterations in the endomembrane 
systems of the parasite, such as a greater amount of apparently empty spaces that De Pablo et al. (2010) 
attribute to a possible collapse of the Golgi apparatus. Disturbances in external and nuclear membranes 
were also shown and ascribed to a general obstruction of protein turnover, which would delay the 
functionality of those proteins necessary for the structural maintenance of the membranes. De Pablo et al. 
(2010) also presented the anti-parasitic effect of maslinic acid in Gallus domesticus chicks infected with 
Eimeria tenella. The animals were fed a maslinic-acid supplemented diet (90 ppm) for 21 days, and this 
treatment caused a reduction in the release of oocysts in the faeces by 80.1%, being more effective than 
the positive control with sodium salinomycin (60 ppm). Histological evaluation of the caeca exposed that 
the characteristic lesions of this coccidiosis were less evident in the animals that had received maslinic 
acid. Moreover, the body weight gain was significantly higher in treated animals compared to the positive 
control and the uninfected group, showing that besides the anticoccidial activity, the triterpene improved 




Maslinic acid has also been reported to be effective against different species of the genus Plasmodium, 
responsible of causing malaria (Moneriz et al., 2011). In vitro experiments using erythrocytes infected 
with Plasmodium falciparum established that maslinic acid (0.1−200 μM) inhibited the growth of the 
parasite dose-dependently (Moneriz et al., 2011). At a concentration of 30 μM (close to the IC50), 
parasitaemia was reduced to 4% by maslinic acid (compared to 8% in untreated red blood cells) and 
reduced the cell cycle, since only the infective (schizonts) and immature (new rings) forms, but not the 
mature forms (trophozoites), were observed in the erythrocytes. However, the exclusion of maslinic acid 
from the medium allowed the infection to recommence, meaning that the triterpene acts as a parasitostatic 
agent (Moneriz et al., 2011).  
 
This effect was further recognized in vivo with ICR mice infected with the lethal strain of Plasmodium 
yoelii (Moneriz et al., 2011). The intraperitoneal injection of 40 mg/kg for 4 days increased the survival 
rate of the animals to 80%, compared to 20% found in animals without any experimental intervention, and 
this was related with a seizure of the maturation of the parasite in the erythrocytes. In addition, the 
animals that survived the primary infection were re-infected with an identical second infection 40 days 
later. Parasitaemia was observed for the following 30 days but no parasites were identified, signifying that 
mice were completely protected against the parasite (Moneriz et al., 2011). Further research on the 
mechanism of action underlying the antimalarial activity of maslinic acid reported that the compound 
hinders the growth of the parasite inside the erythrocytes by hindering various proteins (Moneriz et al., 
2011).  
 
Anthelmintics targeting the intestinal adults and muscle-dwelling larvae of Trichinella spp. have been 
tried, with limited success. Mukaratirwa et al. (2014) aimed at determining the efficacy of maslinic acid 
and fenbendazole on muscle larvae of Trichinella zimbabwensis in laboratory rats. Sprague–Dawley rats, 
with an average weight of 270 g and 180 g for males and females respectively, were infected with T. 
zimbabwensis larvae. Infected rats were randomly allocated to three groups which were exposed to single 
treatments with each of maslinic acid, fenbendazole and a combination of both on day 25 post-infection 
(pi), and three groups which were exposed to double treatments with each of these drugs and a 
combination on days 25 and 32 pi. The untreated control group received a placebo. In single-treatment 
groups, the efficacy of each treatment, measured by rate of reduction in muscle larvae, was significant (P 
< 0.001) for both drugs compared to the untreated control group (Mukaratirwa et al., 2014). There was no 
apparent synergistic effect on the combination of the two drugs in reducing the muscle larval burden, 
either in single or double treatments (Mukaratirwa et al., 2014). In all the treatment regimens, the 
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reductions were significant (P < 0.001) when compared to the untreated control and not significant when 
the single treatments were compared with the double treatments (P > 0.05) (Mukaratirwa et al., 2014). 
Mukaratirwa et al. (2014) concluded that the efficacy of maslinic acid against larval stages of T. 
zimbabwensis in rats was similar to that of fenbendazole, with no side-effects observed, making maslinic 
acid a capable anthelmintic against larval stages of Trichinella species.  
 
To sum up, numerous lines of data show maslinic acid as an antiparasitic and/or anthelmintic agent. More 
research is necessary in order to confirm its efficacy in target species, which would permit the use of 
maslinic acid either alone or in combination with other therapeutic strategies for the treatment of 
parasitoses. Maslinic acid has shown that is has potential antimalarial and anthelmintic properties, which 
is why our main goal on this study is to determine if it is effective on the co-infection of malaria and 
tissue-dwelling nematode.  
 
2.12 Conclusion 
There are few studies that focus on host-parasite interaction and disease outcomes that are elicited by 
tissue-dwelling parasites during co-infection with malaria. This hinders data on understanding the 
mechanisms and outcomes of tissue-dwelling nematodes and co-infection with malaria. This lack of data 
makes it hard to develop diagnosis, vaccine development, drug discovery and management and control of 
these emerging and re-emerging parasites. Therefore, more studies are significant in addressing the lack 
of data and heterogeneity of results reported during STHs, schistomes and filarial worm co-infection with 
malaria. These future studies should be focused on developing new drug strategies designed at controlling 
the co-infection f tissue-dwelling helminths and protozoa especially in sub-Saharan Africa. The use of the 
future different study designs and approaches, as well as different tissue-dwelling helminths and protozoa 
will provide very important information that can be used in humans. The data from this study will useful 
in providing a new potential drug that has an effect on the co-infection tissue-dwelling helminths and 
malaria.    
 










Materials and methods 
 
3.1 Ethical statement 
All animal procedures and protocols were approved by University of KwaZulu-Natal (UKZN) Animal 
Ethics committee (ref. no. 064/14/Animal) in accordance with South African National Legislation 
Regulations in respect to animal husbandry, experimentation and welfare of laboratory animals for 
biomedical research. 
 
3.2 Experimental animals 
Fifty-four Sprague-Dawley male and female rats with an average weight of 150 and 200g were sourced 
from University of KwaZulu-Natal, South Africa. The rats were maintained at the Biomedical Resources 
Unit (BRU) of UKZN, Westville campus, under specific pathogen free conditions in individually 
ventilated metabolic cages. They were randomly assigned into nine groups with males and females kept 
separate, and fed daily heat sterilized pelleted food (Meadow Feeds RSA) and clean water was supplied 
ad libitum. 
3.3 Parasite strains 
Plasmodium berghei ANKA strain which was kindly donated by the University of Cape Town malaria 
research group was used to induce malaria infections in rats. Stock rats were sacrificed and blood was 
collected by cardiac puncture. The blood was collected into EDTA tubes and spun at maximum speed for 
5 minutes. Serum was separated from the red blood cells which was then mixed with freeze mix for 
storage at a -80ºC freezer for further use. 
Trichinella zimbabwensis (Code ISS1209) was isolated from stock rats previously infected and 
maintained at the BRU (UKZN) by repeated passages in rats. Carcasses of rats were digested with tissue 
digestive fluid according to the method described by Pozio et al. (2002) and the dose of larvae 
administered orally to each experimental animal was 3 larvae per gram of animal body weight 
administered as described by Mukaratirwa et al. (2001). 
 
3.4 Experimental design 
The study design is shown in Table 1. Rats were randomly assigned into nine equal groups six rats each; 
(A) Co-infected and treated with maslinic acid, (B) Co-infected and treated with chloroquine, (C) Co-
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infected and treated with maslinic acid and chloroquine, (D) malaria infected and treated with 
chloroquine, (E) malaria infected and treated with maslinic acid, (F) malaria infected and given placebo 
(distilled water) (control), (G) Trichinella-infected and treated with maslinic acid, (H) Trichinella-
infected and treated with chloroquine, and (I) Trichinella-infected and given placebo (control). At day 0 
post infection (pi), rats in groups A, B, C, G, H and I were infected with 3 muscle larvae per gram of 
animal body weight through oral dose as described by Mukaratirwa et al. (2001). At day 25 pi, rats in 
groups G and H were treated with maslinic acid at 2.5mg/kg body weight and chloroquine at 100mg/kg 
body weight, respectively. At day 0, rats in groups D, E and F and at day 30 pi, rats in groups A, B and C 
were inoculated with 1 x 105 infected red blood cells (iRBC) P. berghei parasites according to procedures 
described by Wang et al. (2014). 
Table 1. Summary of experimental design on the efficacy of maslinic acid and chloroquine on the co-
infection of Plasmodium berghei and Trichinella zimbabwensis in rats. 
Group Day of infection  Parasite Treatment 
day(s) 








P. berghei   Maslinic 
acid 
Chloroquine  
A 0  30  +  +  9‐12  +  ‐  42 
B 0  30  +  +  9‐12  ‐  +  42 
C 0  30  +  +  9‐12  +  +  42 
D   0  ‐  +  9‐12  ‐  +  13 
E   0  ‐  +  9‐12  +  ‐  13 
F   0  ‐  +  ‐  ‐  ‐  13 
G 0    +  ‐  25  +  ‐  42 
H 0    +  ‐  25  ‐  +  42 
I 0    +  ‐  ‐  ‐  ‐  42 
 
 
3.5 Determination P. berghei parasitaemia and T. zimbabwensis muscle larvae 
Rats infected with P. berghei were monitored daily for parasitaemia by Giemsa-stained thin blood smears 
prepared using tail blood starting from day 4 pi until day 13 pi. The number of malaria parasites per µL of 
whole rat blood was derived from counting of iRBCs in at least 10 high power fields. Agility, demeanor, 
appetite, posture and fur scores were used to determine experimental humane end points according to 
UKZN animal experimentation standard operating procedures. Muscle larvae in rats infected with T. 
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zimbabwensis were determined from whole carcasses of rats at the endpoint of the experiment by the 
standard HCl-pepsin digestion method (Pozio et al., 2002).  
 
3.6 Drug efficacy determination 
Treatment schedules of rats infected with maslinic acid and chloroquine are shown on Table 1. Starting 
on day 9 till day 12 post malaria-infection, rats in groups A and E were treated with maslinic acid at 
2.5mg/kg body weight administered orally. Starting from day 9 till day 12 post malaria-infection, rats in 
groups B and D were treated with chloroquine at 100mg/kg body weight administered orally. Starting 
from day 9 till day 12, rats in group C were treated with a combination of maslinic acid and chloroquine 
at 2.5mg/kg and 100mg/kg body weight administered orally. At day 25 post Trichinella-infection, rats in 
groups G and H were treated with maslinic acid and chloroquine at 2.5 mg/kg and 100mg/kg body weight 
administered orally, respectively.  
 
3.7 Termination of animals 
On day 13 post treatment all P. berghei and co-infected rats were sacrificed using halothane inhalation in 
line with ethical guideline, including P. berghei control group. All rats infected with T. zimbabwensis 
only were sacrificed 42 days post infection, including T. zimbabwensis control group. Carcasses of rats 
infected with Trichinella were digested with tissue digestive fluid according to the method described by 
Pozio et al. (2002) for the recovery of larvae in the muscle. 
 
3.8 Data analysis 
General Linear Models Procedure was implemented in the SPSS version 23 program (2015) to assess the 
efficacy of the drug regimens against the control using the log transformed mean larval counts and 
parasitaemia mean. Multiple pairwise Bonferroni was used to assess the efficacy between the treatment 
regimens. Graphs were constructed on Graph Prism version 6 (2015). Efficacy rates for each drug and 
combination were calculated as a percentage of recovered larvae versus those recovered from the control 
rats for Trichinella and for P. berghei it was calculated as a percentage of parasitaemia at day 13 post 
treatment (pt) versus parasitaemia at day 9 post infection for malaria (De la Rossa et al., 2007). A 
Regression Linear model was implemented in the SPSS version 23 program (2015) to assess the 









Table 2. Log-transformed least square means (LSM) of Trichinella zimbabwensis larval counts following 
a single treatment (on day 25pi) and Plasmodium berghei parasitaemia following treatments (on days 9, 
10, 11, 12pi) respectively, and % reduction following treatment regimen with maslinic acid, chloroquine 
and the combination of the two. CI, 95% confidence interval, N/A, not applicable. 
 
 
4.1 Larval reduction after treatment 
Maslinic acid (P. berghei + T. zimbabwensis), chloroquine (P. berghei + T. zimbabwensis), maslinic acid 
and chloroquine (P. berghei + T. zimbabwensis), maslinic acid (T. zimbabwensis) and chloroquine (T. 
zimbabwensis) single treatments cleared 91.3%, 95.3%, 89.8% and 88.7% of the larvae, respectively 
(Table 2). All treatments infected with T. zimbabwensis after day 25 pi from each drug regimen reduced 
the larvae. There was no significant difference in the reduction rate among the treated groups (P > 0.05). 
The Bonferroni pairwise comparison of the efficacy of the five drug regimens showed a significant 
reduction in larval counts compared to the untreated control group (P < 0.05) (Table 3). However, there 
was no significant difference in the larval counts among the treated groups, except among maslinic acid 
(P. berghei + T. zimbabwensis) and chloroquine (T. zimbabwensis), chloroquine (P. berghei + T. 
zimbabwensis) and maslinic acid (T. zimbabwensis), maslinic acid and chloroquine (P. berghei + T. 










91.3  2.11  1.862 ‐ 2.366  74  10.34  7.935‐12.797 
Chloroquine 
(co‐infection) 












88.7  2.88  2.663 ‐ 3.137  93.7  9.30  6.762‐11.831 
Untreated 
control 
N/A  3.73  3.473 ‐ 3.977  N/A  15.75  12.879‐18.629 
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(T. zimbabwensis) (P < 0.05) (Table 3). There was no apparent synergistic effect observed in the 
combination of maslinic acid and chloroquine in reducing larval burden (Table 2). While there was no 
significant difference in the efficacy between most drug regimens, co-infected groups treated with 
maslinic acid, chloroquine and the combination of maslinic acid and chloroquine, were slightly more 
effective than the groups infected with T. zimbabwensis only and treated with maslinic acid and 
chloroquine (Table 2). The group infected with T. zimbabwensis only and treated with chloroquine had 
the highest mean of larval counts compared to other treatment regimens (Table 2). Figure 8 shows the 
log-transformed square means of Trichinella and the control group had the highest mean square. 
 
Table 3. Multiple pairwise comparisons of least square means derived from the Bonferroni test of 




















  0.000*  0.000*  0.000*  0.000*  0.001* 
Maslinic acid 
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0.000*    1  1  1  0.002* 
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(co‐infection) 




















Table 4. Multiple pairwise comparisons of means derived from the Bonferroni test of subsequent 










































0.003*  1  1  1  1   
 
4.2 Parasitaemia reduction after treatment 
The reduction rate in parasitaemia in rats infected with P. berghei alone and treated with maslinic acid 
and chloroquine was 93.3% and 93.7%, respectively, while the reduction rate in parasitaemia in rats co-
infected with P. berghei and T. zimbabwensis, treated with maslinic acid, chloroquine and a combination 
of maslinic acid and chloroquine was 74%, 95.8% and 95.5%, respectively (Table 2). There was no 
significant difference in the reduction rate among the treated groups (P > 0.05). The Bonferroni pairwise 
comparison of the efficacy of the five drug regimens showed that there was a significant reduction in 
parasitaemia  compared to the untreated control group (P < 0.05), however there was no significant 
difference in parasitaemia among the treated groups (P > 0.05) (Table 4). There was no apparent 
synergistic effect observed in the combination of maslinic acid and chloroquine in reducing parasitaemia 
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(Table 2). The reduction rate in parasitaemia for the co-infected group treated with chloroquine and the 
combination of maslinic and chloroquine was slightly more effective compared to other treated groups 
(Table 5). 
Nine rats died during the course of the experiment. Of the nine rats that died, three were from the group 
co-infected with P. berghei and T. zimbabwensis and treated with the combination of maslinic acid and 
chloroquine, three from the untreated control group, one from the group infected with P. berghei only and 
treated with maslinic acid and two from the group infected with P. berghei only and treated with 
chloroquine. No rats died from the two groups co-infected with P. berghei and T. zimbabwensis and 
treated with maslinic acid and chloroquine, respectively.  
 
Figure 6. Mean percentage of parasitaemia of rats co-infected with Plasmodium berghei and Trichinella 
zimbabwensis and treated from day 9 to 13 post-infection. 
 
Figure 7. Mean percentage of parasiatemia of rats infected with Plasmodium berghei only and treated 






4.3 Drug efficacy determination 
Blood-stage of P. berghei parasite was observed on the thin blood smears collected from treatment 
regimens including the untreated control group on day 4 post-infection (Figure 6). All animals were 
positive for the parasite by day 4 post-infection (Figure 6). The mean parasitaemia peaked on day 6 post-
infection (23.7%) on rats infected with P. berghei only and treated with chloroquine, while the mean 
parasitaemia peaked on day 9 post-infection for rats infected with P. berghei only and treated with 
maslinic acid (28.1%) (Figure 7). In rats co-infected with P. berghei and T. zimbabwensis treated with 
maslinic acid, mean parasitaemia peaked on day 8 post-infection (22.2%) (Figure 6). However the mean 
parasitaemia recorded peaked on day 9 post-infection in rats co-infected with P. berghei and T. 
zimbabwensis and treated with chloroquine and the combination of maslinic acid and chloroquine (31.9% 
and 24.7) (Figure 6). A similar trend was followed by all treatment regimens, except for the untreated 
control group where mean parasitaemia peaked on days 6, 8, 9, and 12 post-infection (Figure 6 and 7). On 
the day treatment was administered to the rats the mean parasitaemia started decreasing drastically post-
treatment on all treatment regimens (Figure 6 and 7). The untreated control group however had a different 
trend where mean parasitaemia decreased significantly from 26.4% to 9.4% from day 7 to day 8 post-
infection (Figure 6 and 7). After day post-infection mean parasitaemia increased again and reached a peak 
at day 12 post-infection (Figure 6 and 7). 
Table 5 shows that maslinic acid (P. berghei + T. zimbabwensis) had the fastest decrease in parasitaemia 
after treatment was administered from day 9 pi with a regression slope of -2.67±0.85, compared to the 
untreated control which had a regression slope of 0.99±1.35. Chloroquine (P. berghei + T. zimbabwensis) 
and maslinic acid (P. berghei) both had the slowest decrease in parasitaemia after treatment was 









Table 5. Prediction equations for the rate of change in parasitaemia following treatments (on days 9, 10, 
11, 12 pi) with maslinic acid, chloroquine and the combination of maslinic acid and chloroquine. CI, 95% 
confidence interval; SE, standard error; P < 0.05, significant; NS, not significant. 
Treatment 
regimens 
Constant ± SE Regression 
Coefficient ± SE
Goodness of 







Significance level  
Maslinic acid (P. 
berghei) 
91.60 ± 12.35 -7.22 ± 1.11 93.3 (-10.76) - (-
3.68) 
*** (P < 0.001) 
Chloroquine (P. 
berghei) 
39.78 ± 12.35 -3.24 ± 0.90 81.2 (-6.12) - (0.38) * (P < 0.05) 
Maslinic acid (P. 
berghei + T. 
zimbabwensis) 
33.40 ± 9.47 -2.67 ± 0.85 76.5 (-5.39) – (0.05) NS (P > 0.05) 
Chloroquine (P. 
berghei + T. 
zimbabwensis) 
90.30 ± 26.40 -7.37 ± 2.40 76.2 (-11.94) – (0.20) NS (P > 0.05) 
Maslinic acid + 
Chloroquine (P. 
berghei + T. 
zimbabwensis) 
74.34 ± 17.2 -6.04 ± 1.55 83.5 (10.98) – (-1.10) *(P < 0.05) 






Figure 8. Log-transformed least square means of Trichinella zimbabwensis larvae on infected rats 































































Discussion and conclusion 
 
5.1 Discussion  
It is expected that a third of the world’s population, mostly those living in the tropics and sub-tropics, are 
infected with STHs or one or more of the species of Plasmodium (Soliman et al., 2011). Malaria and 
intestinal helminths are parasitic diseases causing morbidity and mortality in most tropical parts of the 
world (Ojurongbe et al., 2011). These parasites are especially co-endemic in children who live in the 
endemic regions of sub-Saharan Africa, resulting in a high rate of co-infection (Ojuronge et al., 2011). 
Naturally associated infections could cause modifications of the specific immune response to each 
pathogen and thus modification of clinical expression (Ojuronge et al., 2004). Helminths can either 
improve (Ojuronge et al., 2004) or worsen (Nacher, 2011) malaria severity. The interaction between 
helminths and malaria could function in either way (Ojurongbe et al., 2011). Helminths may either 
change susceptibility to clinical malaria or malaria may affect the clinical consequences of helminth 
infection (Ojurongbe et al., 2011). 
The results of the present study showed that maslinic acid and chloroquine were efficacious in reducing 
larval burden of T. zimbabwensis and malaria parasitaemia of P. berghei in both co-infected groups and in 
groups infected with P. berghei only and T. zimbabwensis only. However the efficacy of the combination 
of the two drugs did not surpass the efficacy of the individual drugs in clearing both P. berghei and T. 
zimbabwensis. This is in agreement with Mukaratirwa et al. (2014) who demonstrated that the 
combination of maslinic acid and fenbendazole had no apparent synergistic effect. Mukaratirwa et al. 
(2014) also showed that maslinic acid was efficacious in reducing T. zimbabwensis larvae after single or 
double treatment. Maslinic acid has been previously reported to be effective against different species of 
Plasmodium (Moneriz et al., 2011). The results found from this study further prove that maslinic acid is 
indeed effective against Plasmodium and T. zimbabwensis as it was able to reduce parasitaemia of P. 
berghei in co-infected groups and in groups only infected with P. berghei and reduce larval burden in all 
treatment regimens. 
Moneriz et al. (2011) demonstrated that maslinic acid inhibited the growth of the parasite in in vitro 
experiments using erythrocytes infected with P. falciparum. Chloroquine also proved to be efficacious, 
especially in reducing malaria parasitaemia in co-infection of P. berghei and T. zimbabwensis and in 
groups infected with P. berghei only. Results from this study confirm previous studies (Farooq and 
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Mahajan, 2004; Wensdorfer and Payne, 1991). However chloroquine did not prove to be as efficious in 
reducing T. zimbabwensis larvae compared to other treatment regimens. A similar study by Danesvar et 
al. (2010) showed that chloroquine was associated with initial parasite clearance that is both faster in 
knowlesi malaria than vivax malaria. However they are also showed chloroquine resistance after early 
treatment failure (Danesvar et al., 2010). Similar results were also observed in another study where 
chloroquine was used to treat P. vivax in comparison with other drugs such as fixed dose combination 
(FDC) of arterolane maleate and piperaquine phosphate (PQP) (Valecha et al., 2016). The results showed 
that 100% of patients treated with FDC of arterolane maleate and PQP were aparasitaemic and afebrile at 
day 3 compared to 99.3% of patients on chloroquine treatment. The efficacy was more than 95% at 72h in 
both treatment groups (Valecha et al., 2016). The efficacy of chloroquine to Trichinella cannot be 
compared to any previous literature. The literature available for the effect of chloroquine against 
ascariasis is more than 55 years and chloroquine was found to be not effect against this helminth.  
Groups co-infected with P. berghei and T. zimbabwensis and treated with either maslinic acid and/or 
chloroquine had the highest reductions in terms of larvae and malaria parasitaemia, except for the group 
co-infected with P. berghei and T. zimbabwensis and treated with maslinic acid which had the lowest 
efficacy in malaria reduction. These results suggest that T. zimbabwensis and P. berghei were interacting 
with the drugs, in this case to reduce infection severity. A similar study showed tissue-dwelling 
nematodes and malaria interact to either reduce or increase the prevalence (Onkoba et al., 2015). There 
are no previous studies on the efficacy of a drug on the co-infection of tissue-dwelling nematodes and 
malaria. The influence of tissue-dwelling nematodes on the period of a malaria episode is not known 
(Nacher, 2011). However, they appear to decrease some symptoms of malaria that can lead patients to 
pursue treatment (Onkoba et al., 2015).  
Maslinic acid treated group which had been infected with P. berghei only did not show the same peaking 
and decline of parasitaemia prior to the treatment on day 9 pi as the control and chloroquine treated 
groups. This could be immunity had not been acquired as peak levels of parasitaemia was on day 9 pi. 
The untreated group, and co-infected groups reached peak levels of parasitaemia which reduced before 
treatment was administered on day 9 post-infection. This could be as a result of the rats acquiring 
immunity and the co-infection confers early protection. Similar studies have shown that immunization 
with sporozoit forms induces more than 90% protection in rodents and humans (Friesen and 
Matuschewski, 2011; Hoffman et al., 2002). Sauerwein et al. (2012) have explored the idea that using 
drugs with naturally acquired infection could affect the induction of protective immunity. An example of 
such drugs is IPT where parasite exposure is less to undesired sub therapeutic drug concentrations while 
at the same time allowing an effective generation of natural immunity (Schellenberg et al., 2006).  
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In this study we observed that early death occurred in the malaria infected groups compared to co-infected 
groups that had sustained parasitaemia. In our current study we have shown that the co-infection of P. 
berghei and T. zimbabwensis after treatment with maslinic acid and chloroquine reduced muscle larvae 
and parasitaemia. Therefore, we deduce that the use of maslinic acid as an anthelmintic and anti-malaria 
drug in Sprague-Dawley rats has an effect on the co-infection of P. berghei and T. zimbabwensis.  
 Rebound of malaria was not assessed in our study but studies have showed that rebound of malaria 
usually occur from 3 months to 1 year after discontinuation of chemoprophylaxis (Geerligs et al., 2003). 
Geerligs et al. (2003) also showed that of the twelve studies investigating rebound malaria or 
parasitaemia, nine did not show increased clinical malaria or parasitaemia. Similar results were also found 
in a Nigerian study that investigated the effects of chloroquine prophylaxis in children (Bradley-Moore et 
al., 1985). 
5.2 Conclusion 
Because of rapid growth in drug resistance, potential new drug strategies which are cost-effective are 
needed. A huge population especially in SSA are being infected with more than one pathogen and new 
drug targets to treat and control co-infections and not just one pathogen are needed. In view of many 
important needs and limited resources, a package of interventions to substantially decrease the co-
infection of malaria and helminths is unfortunately not affordable to very low-income countries 
This study observed that maslinic acid and chloroquine does in fact reduce muscle larval burden and 
parasitaemia co-infection of both P. berghei and T. zimbabwensis in Sprague-Dawley rats. Drug 
combination is most widely used in treating the most dreadful diseases, such as cancer and AIDS. The 
main aim of drug combination is to achieve synergistic therapeutic effect, dose and toxicity reduction. 
The present study did not achieve a synergistic effect on the drug combination. Therefore, more studies 
need to be done to evaluate drug combinations. 
Humans are exposed to many pathogens on a basis. There are some suggestions that infections such as 
those caused by helminths and by the malaria parasite can interact and affect the immune responses and 
clinical outcomes, but more studies are needed on how tissue dwelling nematodes interacts with the 
immune system to help detoriate or increase malaria episode. Globally, many people are co-infected with 
malaria and helminths and the influence of helminth infections on the course of malaria infection needs 
more careful investigation. There also needs to be more studies on the co-infection of tissue-dwelling 
nematodes and malaria on either immune responses or host-pathogen interaction.  Each type of tissue-
dwelling helminth infection should be studied separately, since they might have different effects on the 
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course of malaria. Treatment of tissue-dwelling helminth infection followed by a detailed follow-up on 
the infection rate and on the symptoms of malaria will be important in establishing the effect of tissue-
dwelling helminth infections on parasitaemia. A better understanding of the interactions between the two 
parasites will improve the evaluation of malaria vaccine trials, drug combinations studies and also reveal 
the implications of anti-helminth treatment programs for the course of malaria disease. Taking into 
account the results of this study and previous studies and the continuing problem of drug resistance, 
maslinic acid is one of the promising natural compounds to exhibit both anthelmintic and anti-malarial 
activities, and may be relevant in the treatment and control of helminths and malaria in endemic areas. 
These findings provide new important knowledge of co-infections with malaria parasites and tissue-
dwelling nematodes and the protective effect of maslinic acid as an anthelmintic and anti-malaria drug 
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